BioVersys, TASK and GSK receive 2.7 million Euro from EDCTP for Phase 2a Clinical Trial
BVL-GSK098 AND ETHIONAMIDE COMBINATION IS BEING DEVELOPED FOR THE TREATMENT OF MULTI-DRUG RESISTANT TUBERCULOSIS INFECTIONS
2021.02.24.BioVersys_PR_EDCTP_Grant_Final1